In 1948, Gomori1 reported increased amounts of phosphamidase in malignant tissue. This observation implied that it might be possible to synthesize a phosphamide ester of nitrogen mustard which could be converted to an active cytotoxic form within malignant tissue. Theoretically, such a compound would show cytotoxic activity only, or at least maximally, within the abnormal tissue cells. A compound with these properties was produced in 1957 by Arnold, Bourseaux, and Brock.2 This compound has the structure shown in Figure 1.
This agent has been used in the therapy of various solid tumors and hematologic malignancies with varying success. Preliminary observations on animal and human studies of the drug have been summarized by Lane,3 Venditti, Humphreys, and Goldin,4 and Coggins, Ravdin, and Eisman.5
Because of the theoretical advantages of such an agent, an evaluation of the usefulness of cyclophosphamide (Cytoxan) in the therapy of mycosis fungoides
ABELE DC, DOBSON RL. The Treatment of Mycosis Fungoides with a New Agent, Cyclophosphamide (Cytoxan). Arch Dermatol. 1960;82(5):725–731. doi:10.1001/archderm.1960.01580050067008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: